تقرير
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.
| العنوان: | SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. |
|---|---|
| المؤلفون: | Corbett, Kizzmekia S, Edwards, Darin, Leist, Sarah R, Abiona, Olubukola M, Boyoglu-Barnum, Seyhan, Gillespie, Rebecca A, Himansu, Sunny, Schäfer, Alexandra, Ziwawo, Cynthia T, DiPiazza, Anthony T, Dinnon, Kenneth H, Elbashir, Sayda M, Shaw, Christine A, Woods, Angela, Fritch, Ethan J, Martinez, David R, Bock, Kevin W, Minai, Mahnaz, Nagata, Bianca M, Hutchinson, Geoffrey B, Bahl, Kapil, Garcia-Dominguez, Dario, Ma, LingZhi, Renzi, Isabella, Kong, Wing-Pui, Schmidt, Stephen D, Wang, Lingshu, Zhang, Yi, Stevens, Laura J, Phung, Emily, Chang, Lauren A, Loomis, Rebecca J, Altaras, Nedim Emil, Narayanan, Elisabeth, Metkar, Mihir, Presnyak, Vlad, Liu, Catherine, Louder, Mark K, Shi, Wei, Leung, Kwanyee, Yang, Eun Sung, West, Ande, Gully, Kendra L, Wang, Nianshuang, Wrapp, Daniel, Doria-Rose, Nicole A, Stewart-Jones, Guillaume, Bennett, Hamilton, Nason, Martha C, Ruckwardt, Tracy J, McLellan, Jason S, Denison, Mark R, Chappell, James D, Moore, Ian N, Morabito, Kaitlyn M, Mascola, John R, Baric, Ralph S, Carfi, Andrea, Graham, Barney S |
| المصدر: | bioRxiv |
| بيانات النشر: | PubMed Central |
| سنة النشر: | 2020 |
| المجموعة: | PubMed Central (PMC) |
| الوصف: | A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation. |
| نوع الوثيقة: | report |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1101/2020.06.11.145920Test; https://pubmed.ncbi.nlm.nih.gov/32577634Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301911Test/ |
| DOI: | 10.1101/2020.06.11.145920 |
| الإتاحة: | https://doi.org/10.1101/2020.06.11.145920Test https://pubmed.ncbi.nlm.nih.gov/32577634Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301911Test/ |
| رقم الانضمام: | edsbas.FF6E5BC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1101/2020.06.11.145920 |
|---|